We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.03 | -1.06% | 96.47 | 97.47 | 96.85 | 97.21 | 1,426,052 | 01:00:00 |
From May 2019 to May 2024
By Olivia Bugault
Novartis AG said Thursday that it has entered into an agreement for the acquisition of Massachusetts-based neuroscience company Cadent Therapeutics.
Cadent will receive $210 million upfront and up to $560 million in milestone payments, for a potential total of $770 million, Cadent Therapeutics said in a separate statement on Thursday.
"The acquisition adds two new clinical stage programs to the Novartis neuroscience portfolio, one for schizophrenia and the other for movement disorders," the pharmaceutical giant said. The acquisition also includes MIJ821, a clinical stage molecule that Novartis licensed exclusively from Cadent in 2015 for treatment-resistant depression.
With the acquisition, Novartis wants to make progress in developing potential neuropsychiatric medicines, it said.
The deal should close during the first quarter of 2021, Novartis said.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
December 17, 2020 02:30 ET (07:30 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
